192 related articles for article (PubMed ID: 24248694)
1. Pro-surfactant protein B as a biomarker for lung cancer prediction.
Sin DD; Tammemagi CM; Lam S; Barnett MJ; Duan X; Tam A; Auman H; Feng Z; Goodman GE; Hanash S; Taguchi A
J Clin Oncol; 2013 Dec; 31(36):4536-43. PubMed ID: 24248694
[TBL] [Abstract][Full Text] [Related]
2. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
[TBL] [Abstract][Full Text] [Related]
3. Gene polymorphisms of SFTPB rs7316, rs9752 and PAOX rs1046175 affect the diagnostic value of plasma Pro-SFTPB and DAS in Chinese Han non-small-cell lung cancer patients.
Wang K; Huang Q; Zhao G; Yang J; Yang K; Huang Y
J Cell Biochem; 2019 Sep; 120(9):14804-14812. PubMed ID: 31016788
[TBL] [Abstract][Full Text] [Related]
4. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.
Ruhaak LR; Stroble C; Dai J; Barnett M; Taguchi A; Goodman GE; Miyamoto S; Gandara D; Feng Z; Lebrilla CB; Hanash S
Cancer Prev Res (Phila); 2016 Apr; 9(4):317-23. PubMed ID: 26813970
[TBL] [Abstract][Full Text] [Related]
5. Plasma pro-surfactant protein B and lung function decline in smokers.
Leung JM; Mayo J; Tan W; Tammemagi CM; Liu G; Peacock S; Shepherd FA; Goffin J; Goss G; Nicholas G; Tremblay A; Johnston M; Martel S; Laberge F; Bhatia R; Roberts H; Burrowes P; Manos D; Stewart L; Seely JM; Gingras M; Pasian S; Tsao MS; Lam S; Sin DD;
Eur Respir J; 2015 Apr; 45(4):1037-45. PubMed ID: 25614175
[TBL] [Abstract][Full Text] [Related]
6. Experimental study of peripheral-blood pro-surfactant protein B for screening non-small cell lung cancer.
He Y; Jiang Z; Tong F; Li M; Yin X; Hu S; Wang L
Acta Cir Bras; 2017 Jul; 32(7):568-575. PubMed ID: 28793041
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
[TBL] [Abstract][Full Text] [Related]
8. Circulating pro-surfactant protein B as a risk biomarker for lung cancer.
Taguchi A; Hanash S; Rundle A; McKeague IW; Tang D; Darakjy S; Gaziano JM; Sesso HD; Perera F
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1756-61. PubMed ID: 23897585
[TBL] [Abstract][Full Text] [Related]
9. Screening for Lung Cancer: What Comes Next?
Peled N; Ilouze M
J Clin Oncol; 2015 Nov; 33(33):3847-8. PubMed ID: 26304887
[No Abstract] [Full Text] [Related]
10. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
[TBL] [Abstract][Full Text] [Related]
11. Prediction of lung cancer risk using circulating pro-surfactant protein B and high-sensitivity C-reactive protein among Egyptian workers in the rubber industry.
Mourad BH
Toxicol Ind Health; 2020 Apr; 36(4):237-249. PubMed ID: 32419650
[TBL] [Abstract][Full Text] [Related]
12. CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.
Du Q; Li E; Liu Y; Xie W; Huang C; Song J; Zhang W; Zheng Y; Wang H; Wang Q
Cancer Med; 2018 Feb; 7(2):325-335. PubMed ID: 29356357
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.
Omenn GS; Goodman GE; Thornquist MD; Balmes J; Cullen MR; Glass A; Keogh JP; Meyskens FL; Valanis B; Williams JH; Barnhart S; Cherniack MG; Brodkin CA; Hammar S
J Natl Cancer Inst; 1996 Nov; 88(21):1550-9. PubMed ID: 8901853
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
15. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance.
Albanes D; Heinonen OP; Taylor PR; Virtamo J; Edwards BK; Rautalahti M; Hartman AM; Palmgren J; Freedman LS; Haapakoski J; Barrett MJ; Pietinen P; Malila N; Tala E; Liippo K; Salomaa ER; Tangrea JA; Teppo L; Askin FB; Taskinen E; Erozan Y; Greenwald P; Huttunen JK
J Natl Cancer Inst; 1996 Nov; 88(21):1560-70. PubMed ID: 8901854
[TBL] [Abstract][Full Text] [Related]
18. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
19. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
[TBL] [Abstract][Full Text] [Related]
20. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
Maeda J; Higashiyama M; Imaizumi A; Nakayama T; Yamamoto H; Daimon T; Yamakado M; Imamura F; Kodama K
BMC Cancer; 2010 Dec; 10():690. PubMed ID: 21176209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
